Skip to main content

Advertisement

Log in

Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Anti-tumor necrosis factors (Anti-TNFs) are a class of biologic disease-modifying anti-rheumatic drugs indicated for the treatment of moderate-to-severe psoriatic arthritis (PsA). Refractory patients are commonly managed by switching from one anti-TNF to another. To assess the evidence on the effectiveness of anti-TNF cycling in PsA patients, a systematic review of the literature was conducted. MEDLINE- and Embase-indexed English-language publications were systematically searched from 1995 to 2015 for studies assessing real-world effectiveness outcomes of anti-TNF cycling in PsA patients. Of 1086 citations identified, 18 studies were included; most conducted in Europe. Six of seven studies testing between lines found significant differences in effectiveness between earlier and subsequent lines of anti-TNF therapy. First-line therapy yielded better results compared with second-line therapy, and significant differences were observed between second- and third-line anti-TNF treatments. In the only study with multivariate regression testing for predictors of response, Danish registry patients were less likely to respond (American College of Rheumatology 20 % or 50 % response) to a second anti-TNF course if safety, rather than lack of effect, caused them to switch (odds ratio [OR] 0.04; p = 0.003 and OR 0.05; p = 0.03, respectively). Effectiveness of anti-TNFs at second line and later is reported in a small number of real-world studies of PsA patients. Subsequent treatment lines may be associated with less response in some measures. More research is needed to quantify the effectiveness of sequential anti-TNF lines in this progressive population‚ and to compare these effects with responses to drugs with different mechanisms of action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ackermann C, Kavanaugh A (2008) Economic burden of psoriatic arthritis. Pharmacoeconomics 26(2):121–129

    Article  PubMed  Google Scholar 

  2. Olivieri I, D’Angelo S, Palazzi C, Padula A (2010) Challenges in economic evaluation of psoriatic arthritis. J Rheumatol 37(6):1086–1088

    Article  PubMed  Google Scholar 

  3. Christophers E (2001) Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol 26(4):314–320

    Article  CAS  PubMed  Google Scholar 

  4. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17

    PubMed  PubMed Central  Google Scholar 

  5. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML (1990) Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 17(6):809–812

    CAS  PubMed  Google Scholar 

  6. McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42(6):778–783

    Article  CAS  PubMed  Google Scholar 

  7. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez LC (1991) Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 30(4):245–250

    Article  CAS  PubMed  Google Scholar 

  8. Coates LC, Tillett W, Chandler D, Helliwell P (2012) The British Society for Rheumatology 2012 guidelines for the treatment of psoriatic arthritis with biologics. Rheumatology 52(10):1754–7

  9. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D et al (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71(1):4–12

    Article  CAS  PubMed  Google Scholar 

  10. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW et al (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 68(5):1060–1071

    PubMed  Google Scholar 

  11. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B et al (2008) Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35(5):869–876

    CAS  PubMed  Google Scholar 

  12. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT et al (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66(4):498–505

    Article  CAS  PubMed  Google Scholar 

  13. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60(4):976–986

    Article  CAS  PubMed  Google Scholar 

  14. Mease P, Kavanaugh A, Perdok RJ, Kupper H, Lavie F (2010) Comparison of Clinical and Radiologic Treatment Outcomes for Patients with Moderate vs. Severe Psoriatic Arthritis Disease Activity at Baseline: Post-hoc Analysis of ADEPT. Rheumatology 49(suppl 1):i48–i59

    Google Scholar 

  15. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A et al (2006) The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65(8):1038–1043

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289

    Article  CAS  PubMed  Google Scholar 

  17. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264–2272

    Article  CAS  PubMed  Google Scholar 

  18. Gomez-Reino JJ, Carmona L (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8(1):R29

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J et al (2007) Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 66(9):1184–1189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics R (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56(1):13–20

    Article  CAS  PubMed  Google Scholar 

  21. Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D (2010) The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 49(12):2313–2321

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Harrold L, Reed G, Magner R, Shewade A, John A, Greenberg J et al (2014) Comparative effectiveness of rituximab versus subsequent anti-tumor necrosis factor in cumulative prednisone exposure in patients with rheumatoid arthritis with prior exposure to TNFi. Ann Rheum Dis 73(Suppl2):508

    Google Scholar 

  23. Gladman DD (2006) Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? Ann Rheum Dis 65(Suppl 3):iii22–iii24

    PubMed  PubMed Central  Google Scholar 

  24. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S et al (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990–999

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. LA Moher D, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097

    Article  PubMed  PubMed Central  Google Scholar 

  26. Blackler L, Kirkham B, Mercer S (2014) Switching TNFi therapy in psoriatic arthritis. Rheumatology 53:i142–i143

    Google Scholar 

  27. Chimenti MS, Teoli M, Saraceno R, Dattola A, Ventura A, Chiricozzi A et al (2013) Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology 227:305–310

    Article  CAS  PubMed  Google Scholar 

  28. Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD et al (2007) Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 67:717–719

    Article  PubMed  Google Scholar 

  29. Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A et al (2007) Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 66:1393–1397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, Rodevand E et al (2013) Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 72:1840–1844

    Article  CAS  PubMed  Google Scholar 

  31. Gladman DD, Sampalis JS, Illouz O, Guerette B (2010) Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 37:1898–1906

    Article  PubMed  Google Scholar 

  32. Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 65:1213–1223

    Article  CAS  PubMed  Google Scholar 

  33. Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P (2009) Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Ann Rheum Dis 69:352–357

    Article  PubMed  Google Scholar 

  34. Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P (2010) Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden. Arthritis Care Res (Hoboken) 62:1399–1406

    Article  Google Scholar 

  35. Haberhauer G, Strehblow C, Fasching P (2010) Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr 160:220–224

    Article  PubMed  Google Scholar 

  36. Haugeberg G, Gulati AM, Diamantopoulos AP, Hoff M, Kavanaugh A (2013) Anti-TNF drug survival in psoriatic arthritis patients treated in ordinary clinical practice. Ann Rheum Dis 72(Suppl3):967

    Google Scholar 

  37. Mazzotta A, Esposito M, Costanzo A, Chimenti S (2009) Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 10:319–324

    Article  PubMed  Google Scholar 

  38. Morel J, Combe B, Daien C, Lukas C (2015) Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis in routine practice. Ann Rheum Dis 74:867

    Article  Google Scholar 

  39. Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A et al (2007) Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 57:269–275

    Article  PubMed  Google Scholar 

  40. Patel V, Mulla E, Kinder A (2015) Retrospective study on the response and side-effect profile of the second biologics in the management of peripheral psoriatic arthritis. Rheumatology 54(Suppl 1):i137

    Google Scholar 

  41. Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H (2010) Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 12:R117

    Article  PubMed  PubMed Central  Google Scholar 

  42. Soubrier AS, Bele-Philippe P, Cortet B, Ramdane-Sebbane N, Bacle-Boutry MA, Lemeunier L et al (2015) Treatment response, drug survival and safety of anti-tumour necrosis factor (alpha) therapy in 193 patients with psoriatic arthritis: A twelve-year “real life” experience. Joint Bone Spine 82:31–37

    Article  CAS  PubMed  Google Scholar 

  43. Wallis D, Jadon D, Tillett W, Waldron N, Cavill C, McHugh N, et al (2013) Psoriatic arthritis and biologic therapy: Treatment response, drug survival and outcome after switching-an observational study. Ann Rheum Dis 71:691. doi:10.1136/annrheumdis-2012-eular.928

  44. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM (2009) Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 36(2):361–367

    Article  PubMed  PubMed Central  Google Scholar 

  45. Kristensen LE, Lie E, Jacobsson LT, Christensen R, Mease PJ, Bliddal H et al (2016) Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden. J Rheumatol 43(1):81–87

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

All authors designed the study. SC, ALM, and MDB drafted the manuscript with review and revisions by all authors. The authors thank Janet Dooley and Melody Tran for assistance with the manuscript.

Funding

This study was funded by Novartis Pharmaceuticals Corporation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Soumya M. Reddy.

Ethics declarations

Conflict of interest

Sheila Crean, Amber L. Martin, and Meghan D. Burns are employees of Evidera, which received funding from Novartis Pharmaceuticals Corporation in connection with the study on which the manuscript is based. Jacqueline Palmer is employed by Novartis Pharmaceuticals Corporation, which funded this study. Soumya Reddy is a consultant to Novartis Pharmaceuticals Corporation and received honoraria for her work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reddy, S.M., Crean, S., Martin, A.L. et al. Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature. Clin Rheumatol 35, 2955–2966 (2016). https://doi.org/10.1007/s10067-016-3425-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-016-3425-4

Keywords

Navigation